Advanced HER2-Expressing Solid Tumors. research hub

Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors

This study is testing a new drug called BDC-1001, both on its own and with another medicine called Nivolumab. It's for adults with advanced cancers that have a specific marker called HER2. The main goal is to see if these treatments are safe and what side effects they might cause.